Emergence of ceftazidime/avibactam resistance in carbapenem-resistant Klebsiella pneumoniae in China.
暂无分享,去创建一个
B. Hong | M. Akova | Ping Zhang | Yunsong Yu | Qiucheng Shi | Xueqing Wu | Xiao-xing Du | Hua-bing Hu | Xiaoxing Du
[1] R. Humphries,et al. Ceftazidime/avibactam resistance associated with L169P mutation in the omega loop of KPC-2 , 2019, The Journal of antimicrobial chemotherapy.
[2] Clinical,et al. Performance standards for antimicrobial susceptibility testing , 2019 .
[3] S. Pongolini,et al. In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime/avibactam treatment , 2018, The Journal of antimicrobial chemotherapy.
[4] Stephania Stump,et al. Successive Emergence of Ceftazidime-Avibactam Resistance through Distinct Genomic Adaptations in blaKPC-2-Harboring Klebsiella pneumoniae Sequence Type 307 Isolates , 2017, Antimicrobial Agents and Chemotherapy.
[5] Brad Spellberg,et al. Klebsiella pneumoniae Carbapenemase-2 (KPC-2), Substitutions at Ambler Position Asp179, and Resistance to Ceftazidime-Avibactam: Unique Antibiotic-Resistant Phenotypes Emerge from β-Lactamase Protein Engineering , 2017, mBio.
[6] M. Christner,et al. Emergence of ceftazidime/avibactam non‐susceptibility in an MDR Klebsiella pneumoniae isolate , 2017, The Journal of antimicrobial chemotherapy.
[7] B. Kreiswirth,et al. Emergence of Ceftazidime-Avibactam Resistance and Restoration of Carbapenem Susceptibility in Klebsiella pneumoniae Carbapenemase-Producing K pneumoniae: A Case Report and Review of Literature , 2017, Open forum infectious diseases.
[8] M. Ye,et al. High ceftazidime hydrolysis activity and porin OmpK35 deficiency contribute to the decreased susceptibility to ceftazidime/avibactam in KPC-producing Klebsiella pneumoniae , 2017, The Journal of antimicrobial chemotherapy.
[9] M. Arthur,et al. Impaired Inhibition by Avibactam and Resistance to the Ceftazidime-Avibactam Combination Due to the D179Y Substitution in the KPC-2 β-Lactamase , 2017, Antimicrobial Agents and Chemotherapy.
[10] Hongwei Zhou,et al. Nationwide Surveillance of Clinical Carbapenem-resistant Enterobacteriaceae (CRE) Strains in China , 2017, EBioMedicine.
[11] Xiaoling Ma,et al. Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant Klebsiella pneumoniae , 2017, Annals of Clinical Microbiology and Antimicrobials.
[12] B. Kreiswirth,et al. In Vitro Selection of Meropenem Resistance among Ceftazidime-Avibactam-Resistant, Meropenem-Susceptible Klebsiella pneumoniae Isolates with Variant KPC-3 Carbapenemases , 2017, Antimicrobial Agents and Chemotherapy.
[13] R. Bonomo,et al. Activity of ceftazidime/avibactam against isogenic strains of Escherichia coli containing KPC and SHV β-lactamases with single amino acid substitutions in the Ω-loop. , 2015, The Journal of antimicrobial chemotherapy.
[14] D. Ehmann,et al. Kinetics of Avibactam Inhibition against Class A, C, and D β-Lactamases , 2013, The Journal of Biological Chemistry.
[15] Y. Qi,et al. ST11, the dominant clone of KPC-producing Klebsiella pneumoniae in China. , 2011, The Journal of antimicrobial chemotherapy.